The ability of b-rPCN to interact with TLR2 and TLR4 on APCs and the therapeutic effects triggered by such interactions on the course of experimental PCM were already established (Alegre et al., 2014; Alegre-Maller et al., 2014). The gene discussed is TLR2; the disease is paracoccidioidomycosis.